Cebon J - Search Results

1

Immunological effects of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma.

Scott AM, Liu Z, Murone C, Johns TG, MacGregor D, Smyth FE, Lee FT, Cebon J, Davis ID, Hopkins W, Mountain AJ, Rigopoulos A, Hanai N, Old LJ. Scott AM, et al. Among authors: cebon j. Cancer Immun. 2005 Feb 22;5:3. Cancer Immun. 2005. PMID: 15723450 Clinical Trial.

2

Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation.

O'Malley CJ, Rasko JE, Basser RL, McGrath KM, Cebon J, Grigg AP, Hopkins W, Cohen B, O'Byrne J, Green MD, Fox RM, Berndt MC, Begley CG. O'Malley CJ, et al. Among authors: cebon j. Blood. 1996 Nov 1;88(9):3288-98. Blood. 1996. PMID: 8896392 Free article. Clinical Trial.

3

Clinical promise of tumour immunology.

Scott AM, Cebon J. Scott AM, et al. Among authors: cebon j. Lancet. 1997 May;349 Suppl 2:SII19-22. doi: 10.1016/s0140-6736(97)90016-7. Lancet. 1997. PMID: 9164443 Review. No abstract available.

4

Spontaneous T cell responses to melanoma differentiation antigens from melanoma patients and healthy subjects.

Chen Q, Jackson H, Gibbs P, Davis ID, Trapani J, Cebon J. Chen Q, et al. Among authors: cebon j. Cancer Immunol Immunother. 1998 Dec;47(4):191-7. doi: 10.1007/s002620050520. Cancer Immunol Immunother. 1998. PMID: 9875671 Free PMC article.

5

Cardiac metastases from malignant melanoma.

Gibbs P, Cebon JS, Calafiore P, Robinson WA. Gibbs P, et al. Among authors: cebon js. Cancer. 1999 Jan 1;85(1):78-84. Cancer. 1999. PMID: 9921977 Review.

6

A direct comparison of cytolytic T-lymphocyte responses to Melan-A peptides in vitro: differential immunogenicity of Melan-A27-35 and Melan-A26-35.

Chen Q, Jackson H, Cebon J, Gibbs P, Davis ID, Trapani JA. Chen Q, et al. Among authors: cebon j. Melanoma Res. 2000 Feb;10(1):16-25. Melanoma Res. 2000. PMID: 10711636

7

A phase I and pharmacokinetic study of subcutaneously-administered recombinant human interleukin-4 (rhuIL-4) in patients with advanced cancer.

Davis ID, Maher DW, Cebon JS, Green MD, Fox RM, McKendrick JJ, Rybak ME, Boyd AW. Davis ID, et al. Among authors: cebon js. Growth Factors. 2000;17(4):287-300. doi: 10.3109/08977190009028972. Growth Factors. 2000. PMID: 10801077 Clinical Trial.

8

MAGE-12 and MAGE-6 are frequently expressed in malignant melanoma.

Gibbs P, Hutchins AM, Dorian KT, Vaughan HA, Davis ID, Silvapulle M, Cebon JS. Gibbs P, et al. Among authors: cebon js. Melanoma Res. 2000 Jun;10(3):259-64. Melanoma Res. 2000. PMID: 10890380

9

Immunotherapy of melanoma: targeting defined antigens.

Cebon J, MacGregor D, Scott A, DeBoer R. Cebon J, et al. Australas J Dermatol. 1997 Jun;38 Suppl 1:S66-72. doi: 10.1111/j.1440-0960.1997.tb01014.x. Australas J Dermatol. 1997. PMID: 10994477 Review.

10

Exogenous peptides presented by transporter associated with antigen processing (TAP)-deficient and TAP-competent cells: intracellular loading and kinetics of presentation.

Luft T, Rizkalla M, Tai TY, Chen Q, MacFarlan RI, Davis ID, Maraskovsky E, Cebon J. Luft T, et al. Among authors: cebon j. J Immunol. 2001 Sep 1;167(5):2529-37. doi: 10.4049/jimmunol.167.5.2529. J Immunol. 2001. PMID: 11509592

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

304 results

Search Page

Filters